MEDICAL UPDATE: Trial Of Oral Ganciclovir

MEDICAL UPDATE: Trial Of Oral Ganciclovir

Being Alive Newsletter; Beling Alive/Los Angeles - September 93
Mark Katz MD and reported by Jim Stoecker

CMV is one of the opportunistic infections for which no effective prophylaxis is yet available. Now a trial of oral ganciclovir as CMV prophylaxis is getting underway.

Ganciclovir has been used successfully as treatment for CMV. The drug, however, has to be taken intravenously, and this has made its use as prophylaxis impractical. Now an oral form of ganciclovir has been developed and made available for trial.

The National Institute of Allergies and Infectious Diseases is sponsoring the trial which will include 850 subjects throughout the country. One local site for this study is the Krause-Beer Medical Group, where Dr. Bernard McNamara will be conducting the study. Study subjects must have CD4 less than 100 and have been diagnosed with at least one AIDS-defining opportunistic infection. For more information, you can call Dr. McNamara at 213.930.2323.
930900
BA930911

AEGiS is made possible through unrestricted grants from Roxane Laboratories, the National Library of Medicine, and donations from users like you. Always watch for outdated information. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

Copyright © 1993 - Beings Alive. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. Being Alive, 621 N. San Vicente Blvd., West Hollywood, CA 90069, Tel - 310.289.2551; FAX - 310.289.9866; Email: BeiAlive@aol.com http://www.beingalivela.org/

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1993. AEGIS.